Cargando…
Patient reported outcomes for quality of life (QOL) by Expanded Prostate Cancer Index (EPIC) on average 15 years post treatment
OBJECTIVE/PURPOSE: Previously patient reported quality of life (QOL) was reported in men with prostate cancer a mean 2 and 6 years post treatment with open radical prostatectomy (RP), 3D conformal radiation therapy (3D CRT), or (125)I low dose rate (LDR) brachytherapy (BT). Herein we update the resu...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9256969/ https://www.ncbi.nlm.nih.gov/pubmed/35813938 http://dx.doi.org/10.1016/j.ctro.2022.05.007 |
_version_ | 1784741231548432384 |
---|---|
author | Seymour, Zachary A. Daignault-Newton, Stephanie McLaughlin, P.W. Sandler, Howard Jackson, William Johnson, Skyler B. Miller, David Wei, John Sanda, Martin Hamstra, Daniel A. |
author_facet | Seymour, Zachary A. Daignault-Newton, Stephanie McLaughlin, P.W. Sandler, Howard Jackson, William Johnson, Skyler B. Miller, David Wei, John Sanda, Martin Hamstra, Daniel A. |
author_sort | Seymour, Zachary A. |
collection | PubMed |
description | OBJECTIVE/PURPOSE: Previously patient reported quality of life (QOL) was reported in men with prostate cancer a mean 2 and 6 years post treatment with open radical prostatectomy (RP), 3D conformal radiation therapy (3D CRT), or (125)I low dose rate (LDR) brachytherapy (BT). Herein we update the results 15 years post-treatment QOL. MATERIALS/METHODS: The Expanded Prostate Cancer Index (EPIC) domains were scored with differences evaluated at a median 15.8 years follow up based upon mean EPIC summary domains by ANOVA with pairwise post-hoc comparisons adjusted for age. Patient differences of current survey from first cross-section are reported as median change in summary score for each treatment group at median of 2.2 and 6.0, and 15.8 years. RESULTS: Among men still alive response rate was 52% in BT, 60% in 3D CRT, and 62% in RP resulting in 30, 41, and 330 QOL questionnaires to evaluate for each corresponding modality at median follow up of 15.8 years. Men were a mean 75.3, 83.6, and 79.3 years of age after RP, 3DCRT, and BT, respectively. At a median of 15.8 years, there were largely persistent differences in EPIC domains without substantial evolution in QoL from middle time points. Persistent worsening in urinary irritative and bowel domain with 3DRT or BT compared to RP. Trend towards worse urinary incontinence with RP were noted without statistical differences within radiotherapy options. CONCLUSION: As the EPIC patient reported outcomes with the longest follow-up, these data uniquely reveal temporal trends from 2 to 15 years post treatment. However, the treatment modalities of open RP, 3D CRT without image guidance or intensity modulation, and BT without peripheral loading or MRI guidance may not reflect modern techniques. |
format | Online Article Text |
id | pubmed-9256969 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-92569692022-07-07 Patient reported outcomes for quality of life (QOL) by Expanded Prostate Cancer Index (EPIC) on average 15 years post treatment Seymour, Zachary A. Daignault-Newton, Stephanie McLaughlin, P.W. Sandler, Howard Jackson, William Johnson, Skyler B. Miller, David Wei, John Sanda, Martin Hamstra, Daniel A. Clin Transl Radiat Oncol Article OBJECTIVE/PURPOSE: Previously patient reported quality of life (QOL) was reported in men with prostate cancer a mean 2 and 6 years post treatment with open radical prostatectomy (RP), 3D conformal radiation therapy (3D CRT), or (125)I low dose rate (LDR) brachytherapy (BT). Herein we update the results 15 years post-treatment QOL. MATERIALS/METHODS: The Expanded Prostate Cancer Index (EPIC) domains were scored with differences evaluated at a median 15.8 years follow up based upon mean EPIC summary domains by ANOVA with pairwise post-hoc comparisons adjusted for age. Patient differences of current survey from first cross-section are reported as median change in summary score for each treatment group at median of 2.2 and 6.0, and 15.8 years. RESULTS: Among men still alive response rate was 52% in BT, 60% in 3D CRT, and 62% in RP resulting in 30, 41, and 330 QOL questionnaires to evaluate for each corresponding modality at median follow up of 15.8 years. Men were a mean 75.3, 83.6, and 79.3 years of age after RP, 3DCRT, and BT, respectively. At a median of 15.8 years, there were largely persistent differences in EPIC domains without substantial evolution in QoL from middle time points. Persistent worsening in urinary irritative and bowel domain with 3DRT or BT compared to RP. Trend towards worse urinary incontinence with RP were noted without statistical differences within radiotherapy options. CONCLUSION: As the EPIC patient reported outcomes with the longest follow-up, these data uniquely reveal temporal trends from 2 to 15 years post treatment. However, the treatment modalities of open RP, 3D CRT without image guidance or intensity modulation, and BT without peripheral loading or MRI guidance may not reflect modern techniques. Elsevier 2022-06-01 /pmc/articles/PMC9256969/ /pubmed/35813938 http://dx.doi.org/10.1016/j.ctro.2022.05.007 Text en © 2022 Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Seymour, Zachary A. Daignault-Newton, Stephanie McLaughlin, P.W. Sandler, Howard Jackson, William Johnson, Skyler B. Miller, David Wei, John Sanda, Martin Hamstra, Daniel A. Patient reported outcomes for quality of life (QOL) by Expanded Prostate Cancer Index (EPIC) on average 15 years post treatment |
title | Patient reported outcomes for quality of life (QOL) by Expanded Prostate Cancer Index (EPIC) on average 15 years post treatment |
title_full | Patient reported outcomes for quality of life (QOL) by Expanded Prostate Cancer Index (EPIC) on average 15 years post treatment |
title_fullStr | Patient reported outcomes for quality of life (QOL) by Expanded Prostate Cancer Index (EPIC) on average 15 years post treatment |
title_full_unstemmed | Patient reported outcomes for quality of life (QOL) by Expanded Prostate Cancer Index (EPIC) on average 15 years post treatment |
title_short | Patient reported outcomes for quality of life (QOL) by Expanded Prostate Cancer Index (EPIC) on average 15 years post treatment |
title_sort | patient reported outcomes for quality of life (qol) by expanded prostate cancer index (epic) on average 15 years post treatment |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9256969/ https://www.ncbi.nlm.nih.gov/pubmed/35813938 http://dx.doi.org/10.1016/j.ctro.2022.05.007 |
work_keys_str_mv | AT seymourzacharya patientreportedoutcomesforqualityoflifeqolbyexpandedprostatecancerindexepiconaverage15yearsposttreatment AT daignaultnewtonstephanie patientreportedoutcomesforqualityoflifeqolbyexpandedprostatecancerindexepiconaverage15yearsposttreatment AT mclaughlinpw patientreportedoutcomesforqualityoflifeqolbyexpandedprostatecancerindexepiconaverage15yearsposttreatment AT sandlerhoward patientreportedoutcomesforqualityoflifeqolbyexpandedprostatecancerindexepiconaverage15yearsposttreatment AT jacksonwilliam patientreportedoutcomesforqualityoflifeqolbyexpandedprostatecancerindexepiconaverage15yearsposttreatment AT johnsonskylerb patientreportedoutcomesforqualityoflifeqolbyexpandedprostatecancerindexepiconaverage15yearsposttreatment AT millerdavid patientreportedoutcomesforqualityoflifeqolbyexpandedprostatecancerindexepiconaverage15yearsposttreatment AT weijohn patientreportedoutcomesforqualityoflifeqolbyexpandedprostatecancerindexepiconaverage15yearsposttreatment AT sandamartin patientreportedoutcomesforqualityoflifeqolbyexpandedprostatecancerindexepiconaverage15yearsposttreatment AT hamstradaniela patientreportedoutcomesforqualityoflifeqolbyexpandedprostatecancerindexepiconaverage15yearsposttreatment |